Riverain公司推出肺癌诊断CAD系统

 
一种新型计算机辅助检测（CAD）系统，是第一种能够精确辅助放射技师检测早期肺癌的系统。根据美国癌症学会的说法，如果肺癌在比较局限的时候能够被检测或者治疗，患者的5年生存率能够在第I阶段提高495。

这套CAD系统在患者的胸部X线片上检测疑似肺部肿块。然而这套系统并不能够独立鉴别疾病，系统为放射科技师“阅读”X线图像、处理信息、展示资料，以帮助检测病变。

这套系统叫做RapidScreen，是由Riverain医学公司研制开发的，在2001年7月获得了美国食品药品管理局的上市销售以前的批准。这种技术是根据一种能够检测并鉴别87种与单个肺部肿块相关的独特信号的运算法则为基础研制开发的。在临床试验中，放射科技师使用RapidScreen能够将9-14毫米大小的肿瘤鉴别成功率增加23％。

CAD System for Lung Cancer
 
A new computer-aided detection (CAD) system is the first to accurately assist radiologists in detecting early-stage lung cancer. If lung cancer is found and treated while localized, a patient’s five-year survival can increase to 49% at stage I, according to the American Cancer Society.

The CAD system detects suspicious pulmonary nodules on chest x-rays. Whereas it does not identify the disease independently, this system “reads” the x-ray images, processes the information, and displays the data for the radiologist to detect an abnormality.

The system, called RapidScreen, was developed by Riverain Medical
(Miamisburg, OH, USA; www.riverainmedical.com), and received the U.S. Food and Drug Administration (FDA) premarket approval in July 2001. The technology is based on an algorithm to detect and classify 87 exclusive signatures that are associated with solitary pulmonary nodules. In clinical studies, radiologists using RapidScreen improved the identification of tumors between 9-14 mm by 23%.